GlobalData on MSN4 天
Palatin concludes Phase II trial of combination therapy for obesity
"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...
Morningstar5 天
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
The primary endpoint of the Phase 2 BMT-801 clinical trial is to demonstrate the safety and efficacy of co-administration of bremelanotide with tirzepatide on reducing body weight. Patients were ...
Nasdaq5 天
Palatin Technologies Completes Phase 2 Obesity Study On MC4R Bremelanotide And Tirzepatide
(PTN), a biopharmaceutical company, on Thursday announced the completion of its Phase 2 BMT-801 clinical study evaluating the combination of MC4R bremelanotide and GLP-1/GIP tirzepatide for the ...
Finanznachrichten5 天
Palatin Technologies, Inc.: Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide ...
The primary endpoint of the Phase 2 BMT-801 clinical trial is to demonstrate the safety and efficacy of co-administration of bremelanotide with tirzepatide on reducing body weight. Patients were ...